Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$26.63
$0.23(0.84%)
At close: 4:00 PM EDT
$26.63
$0.23(0.84%)
Day’s Range― - ―
52-Week Range$6.25 - $34.39
Previous CloseN/A
Volume1.26K
Average Volume (3M)4.03M
Market Cap
$4.32B
Enterprise Value$3.70K
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$31.99M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding168,610,370
10 Day Avg. Volume2,102,693
30 Day Avg. Volume4,030,720
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.20Price Target Upside65.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital RunwayA ~$566.5M equity raise materially extends Tango’s cash runway into 2030, reducing near-term financing risk and enabling funding of pivotal trials and commercialization prep. This durable capital buffer supports multi-year clinical execution and partnership negotiations without immediate refinancing.
Clinical Proof-of-conceptExceptionally strong early combo efficacy (92% ORR) and move into Phase 3 materially de-risks Tango’s lead program. If reproducible in registrational trials, this can reshape standard of care in MTAP-deleted tumors and materially improve partner/commercial prospects and long-term revenue potential.
Low Leverage & High Gross MarginVery low financial leverage reduces insolvency and interest risks while a ~97% gross margin reflects scalable product economics typical for successful biotech. Together these fundamentals enhance financial flexibility to support R&D and later commercialization capital needs if clinical programs succeed.
Bears Say
High Cash BurnSubstantial negative operating and free cash flows (~-$144M TTM) mean the business consumes capital rapidly. Even with recent financing, sustained burn requires disciplined spend, milestone delivery, or further funding; execution delays could force dilution or program cuts, impacting long-term strategy.
Persistent Net LossesLarge, persistent losses and deeply negative margins indicate the company is far from profitability. Long-term value depends on binary clinical and regulatory outcomes; until commercial products exist, sustained losses will dilute equity and pressure returns for long-horizon investors.
Executive Chair DepartureThe departure of an experienced executive chair during a pivot to late-stage development introduces governance and relationship risk. Although described as orderly, losing a senior leader can affect strategic continuity, partner relations, and investor confidence during critical trial and commercialization planning.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics, Inc.’s price range in the past 12 months?
Tango Therapeutics, Inc. lowest stock price was $6.25 and its highest was $34.39 in the past 12 months.
What is Tango Therapeutics, Inc.’s market cap?
Tango Therapeutics, Inc.’s market cap is $4.32B.
When is Tango Therapeutics, Inc.’s upcoming earnings report date?
Tango Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 87 days.
How were Tango Therapeutics, Inc.’s earnings last quarter?
Tango Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.317 by -$0.053.
Is Tango Therapeutics, Inc. overvalued?
According to Wall Street analysts Tango Therapeutics, Inc.’s price is currently Undervalued.
Does Tango Therapeutics, Inc. pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
What is Tango Therapeutics, Inc.’s EPS estimate?
Tango Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has 168,610,370 shares outstanding.
What happened to Tango Therapeutics, Inc.’s price movement after its last earnings report?
Tango Therapeutics, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.317. Following the earnings report the stock price went down -4.807%.
Which hedge fund is a major shareholder of Tango Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.20 (65.98% Upside)
$44.20 (65.98% Upside)
Blogger Sentiment
Bullish
TNGX Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
294.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
351.42%
Trailing 12-Months
Company Description
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$44.20
▲(65.98% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
9.39% Insiders
7.85% Mutual Funds
70.47% Other Institutional Investors
0.29% Public Companies and Individual Investors